Raji-h4-1BB Cells
-
Cat.code:
raji-h41bb
- Documents
ABOUT
Human 4-1BB-expressing B cells
Raji-h4-1BB cells were developed from the human Raji cell line, a human B lymphocyte-derived cell line, and engineered to stably overexpress the human 4‑1BB gene. Raji cells have been successfully used as target cells in antibody effector studies such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) assays with peripheral T cell-derived Jurkat reporter cells.
4-1BB (also known as CD137 or TNFSF9) is a co-stimulatory immune checkpoint (IC) receptor that belongs to the tumor necrosis factor receptor (TNFR)/TNF superfamily. 4-1BB is expressed on a multitude of cells including activated CD8+ and CD4+ T cells [1]. Upon 4-1BB binding to its ligand, 4-1BBL (CD137L), expressed on antigen-presenting cells (APCs), NF‑κB‑dependent signaling is activated within the T cell, powerfully augmenting T cell activation, proliferation, and survival [1]. Notably, activation of 4-1BB has the capacity to mediate strong effector T cell immune responses and thus, makes it an attractive target for cancer immunotherapy [1,2]. Despite 4-1BB agonistic antibodies eliciting potent anti-tumor responses, monotherapy progress has been limited in the clinic [2]. However, combinational therapies may be promising with a significant synergistic effect observed when used in combination with IC inhibitory antibodies (e.g. Anti-CTLA-4 and Anti-PD-1) [1,2].
Features of Raji-h4-1BB cells:
- Stable overexpression of the human 4-1BB gene
- Characterized by a number of cell-surface expressed markers including the B cell receptor (BCR), CD19, and CD20
- Constitutive expression of various immune checkpoints (ICs) such as CD27, CD70, CD80, PD-L1, and 4-1BBL
Applications for Raji-h4-1BB cells:
- Target cell line for ADCC and ADCP assays using InvivoGen's Jurkat-Lucia™ NFAT-CD16 cells and Jurkat-Lucia™ NFAT-CD32 cells, respectively.
- Target cell line for cell toxicity assays using NK or CAR-T cells
- For use in the development novel human 4-1BB mAbs
Validation of Raji-h4-1BB cells:
- Overexpression of 4-1BB verified by flow cytometry
- Functionally tested as target cells in ADCC assays using anti-human 4-1BB mAbs and Jurkat-Lucia™ NFAT-CD16 cells
- Guaranteed mycoplasma-free
References:
1. Bartkowiak, T. & Curran, M.A. 2015. 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity. Front Oncol 5, 117.
2. Ascierto, P.A. et al. 2010. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol 37, 508-516.
Disclaimer: These cells are for internal research use only and are covered by a Limited Use License (See Terms and Conditions). Additional rights may be available.
SPECIFICATIONS
Specifications
ADCC/ADCP assays using anti-human 4-1BB mAbs and Jurkat-Lucia™ NFAT-CD16 or CD32 cells
Complete IMDM (see TDS)
Tested and validated using PlasmotestTM.
Each lot is functionally tested and validated.
Expression of human 4-1BB has been verified by flow-cytometry.
Induction of antibody-dependent cellular cytotoxicity (ADCC) has been validated using anti-h41BB antibodies and InvivoGen's Jurkat-Lucia™ NFAT-CD16 cells reporter cell line.
CONTENTS
Contents
-
Product:Raji-h4-1BB Cells
-
Cat code:raji-h41bb
-
Quantity:3-7 x 10^6 cells
- 1 ml of Blasticidin (10 mg/ml)
- 1 ml of Normocin™ (50 mg/ml)
Shipping & Storage
- Shipping method: Dry ice
- Liquid nitrogen vapor
Storage:
DOCUMENTS
Documents
Technical Data Sheet
Validation Data Sheet
Safety Data Sheet
Certificate of analysis
Need a CoA ?